Day One Biopharmaceuticals Insider Sold Shares Worth $320,226, According to a Recent SEC Filing
Samuel C. Blackman, Head of R&D, on July 16, 2024, sold 20,000 shares in Day One Biopharmaceuticals (DAWN) for $320,226. Following the Form 4 filing with the SEC, Blackman Samuel C. has control over
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.
Day One Biopharm Price Target Maintained With a $40.00/Share by Piper Sandler
Day One Biopharm Price Target Maintained With a $40.00/Share by Piper Sandler
Piper Sandler Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals(DAWN.US) Director Sells US$131.88K in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Director Ramasastry Saira sold 10,000 shares of common stock on Jun 21, 2024 at an average price of $13.1877 for a total value of $131.88K.Source: Announcement Wh
Form 144 | Day One Biopharmaceuticals(DAWN.US) Director Proposes to Sell 131.88K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 21, $Day One Biopharmaceuticals(DAWN.US)$ Director SAIRA RAMASASTRY intends to sell 10,000 shares of its common stock on Jun 21, with a total market value of approximately
Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Piper Sandler analyst Joseph Catanzaro maintains $Day One Biopharmaceuticals(DAWN.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success ra
H.C. Wainwright Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright analyst Andres Y. Maldonado maintains $Day One Biopharmaceuticals(DAWN.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a succe
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $40 price target.
Capital One Financial Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Capital One Financial analyst Naureen Quibria maintains $Day One Biopharmaceuticals(DAWN.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a suc
Day One Biopharm Price Target Maintained With a $33.00/Share by Needham
Day One Biopharm Price Target Maintained With a $33.00/Share by Needham
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.
Day One Biopharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/19/2024 146.45% Needham $33 → $33 Reiterates Buy → Buy 05/07/2024 146.45% Needham $33 → $33 Reiterates
Needham Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $33
Needham analyst Ami Fadia maintains $Day One Biopharmaceuticals(DAWN.US)$ with a buy rating, and maintains the target price at $33.According to TipRanks data, the analyst has a success rate of 44.4% a
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $39
JonesTrading analyst Soumit Roy maintains $Day One Biopharmaceuticals(DAWN.US)$ with a buy rating, and maintains the target price at $39.According to TipRanks data, the analyst has a success rate of 2
Day One in Licensing Pact With MabCare for Cancer Therapy
Day One Biopharmaceuticals (NASDAQ:DAWN) announced Tuesday that it has reached an exclusive licensing agreement with Chinese biotech MabCare Therapeutics to obtain rights for an experimental cancer therapy.
Express News | Day One Biopharmaceuticals Enters Exclusive Licensing Agreement With MabCare Therapeutics For MTX-13; IND Cleared By FDA In April 2024, Targets PTK7 In Adult And Pediatric Solid Tumors
Express News | Day One Biopharmaceuticals: Got Into Exclusive Licensing Agreement With Mabcare Therapeutics for Mtx-13
Express News | Day One Biopharmaceuticals Inc: Expects First Patient to Be Dosed in Phase I Study in Q4 of 2024 or Q1 of 2025